| KMPH - KemPharm Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2023-08-14 (Delayed quote data ) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, and KP484, are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |